OPR - Delayed Quote • USD GLPG Oct 2024 45.000 put (GLPG241018P00045000) Follow 15.20 0.00 (0.00%) At close: April 23 at 1:43 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for GLPG241018P00045000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: GLPG Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG) Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG) Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround 11 Oversold Biotech Stocks To Buy Right Now Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript Galapagos announces full year 2023 results and outlook for 2024 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline Galapagos presents at EBMT-EHA annual meeting 2024 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
